Genetic Mutations and Family History
38 Articles
PRECEDE Trial Sets Survival Rate Goal
Dr. Raymond Wadlow explains how the PRECEDE trial aims to increase pancreatic cancer survival through earlier detection of high-risk people.
Putting Familial Risk In Perspective
Dr. Alison Klein works to understand the relationship between familial risk and the chances of developing pancreatic cancer.
Meet the Researcher: Nicolette Juliana Rodriguez, M.D., M.P.H.
Learn more about the research interests of Nicolette Rodriguez, M.D., M.P.H., one of the young investigators Let’s Win sponsored at AACR.
Newly Discovered Protein Complex in RAS Pathway May Provide a Treatment Target
Dr. Andrew Aguirre and other researchers from Dana-Farber and the Broad Institute are looking at the RAS pathway for a new target.
New Gene Inhibitor Drug for Patients with MTAP-Deleted Tumors
A new trial targets patients with advanced solid tumors, including pancreatic cancer, with an MTAP-deletion genetic mutation.
New Study to Get More Minorities Involved in Genetic Testing
Dr. Nicolette Rodriguez leads the REGENERATE study to find the best ways to get more Black and Latinx Americans genetic testing for cancer.
Testing an Approved Drug for a Specific Mutation
Researchers are testing a drug combination for melanoma in pancreatic cancer patients with a BRAF genetic mutation.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
Using Molecular Tumor Profiling to Determine the Best Pancreatic Cancer Treatment
A clinical trial looks at whether molecular subtyping of tumors is effective in determining the best pancreatic cancer treatment.
Targeting the Undruggable KRAS Protein
Dr. Shubham Pant is focusing his research on effective treatments for the KRAS mutation, found in 90% of pancreatic cancers.
Testing a PARP Inhibitor for Metastatic Pancreatic Cancer Patients with DNA Repair Mutations
Researchers are testing a PARP inhibitor that is effective for cancers in pancreatic cancer patients with DNA repair mutations.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
Chemotherapy Plus Stem Cell Infusion and Vitamins for BRCA Mutated Pancreatic Cancer
A clinical trial for pancreatic cancer patients with a BRCA mutation uses a combination of chemotherapy, vitamins, and stem cells.
Improving Access to Genetic Testing and Counseling
Dr. Angela Bradbury is leading a study on access to genetic testing and genetic counseling, including a telehealth option.
GENERATE Trial Expands Eligibility
Dr. Sapna Syngal explains the expanded eligibility standards for the GENERATE Study for genetic testing of pancreatic cancer patients and relatives.